TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21163558
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (sesame oil + glibenclamide)
Study: 15638906
Drug: Vardenafil 20
Normalized name: vardenafil 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vardenafil 20 mg
Study: 12170362
Drug: High-dose methyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose methyl prednisolone (30 mg/kg)
Study: 12170362
Drug: Low-dose methyl
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose methyl prednisolone (2 mg/kg)
Study: 10660865
Drug: Inosine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inosine supplementation (10,000 mg.d‐1)
Study: 7749832
Drug: Warfarin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin treatment with INR < 1.7
Study: 7749832
Drug: Warfarin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin treatment with INR 1.7 to 2.5
Study: 7749832
Drug: Warfarin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin treatment with INR > 2.5
Study: 7749832
Drug: Warfarin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin treatment (general)
Study: 7749832
Drug: Warfarin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin treatment in patients with congenital antithrombin III or protein C deficiency
Study: 7749832
Drug: Warfarin discontinuation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin discontinuation in one patient
Study: 7461761
Drug: PPD-G
Normalized name: Purified Protein Derivative - Tuberculin
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPD-G
Study: 29401082
Drug: Delayed initiation
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Delayed initiation of oral feeding (1 week later)
Study: 29401082
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (started oral feeding when physiologically stable)
Study: 15671185
Drug: Enhanced care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced care (active treatment with practice nurses for 24 months)
Study: 12791219
Drug: Analgesics administered
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analgesics administered before surgical evaluation
Study: 10496260
Drug: Immediate-release (IR)
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release (IR) carbidopa/levodopa
Study: 10496260
Drug: Controlled-release (CR)
Normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Controlled-release (CR) carbidopa/levodopa
Study: 7793557
Drug: Bupivacaine 0.25%
Normalized name: BUPIVACAINE 0.25%/NS INJ 400ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.25% 20 ml applied locally to the knee at the end of the procedure (n = 30)
Study: 7793557
Drug: Piroxicam 20
Normalized name: piroxicam 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroxicam 20 mg intramuscularly (n = 30)
Study: 1771701
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg trospium chloride twice daily for 3 weeks
Study: 7044532
Drug: Doxorubicin chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin chemotherapy with radiation therapy
Study: 7044532
Drug: Levamisole immunotherapy
Normalized name: Levamisole
DrugBank: Levamisole (DB00848)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levamisole immunotherapy with radiation therapy
Study: 7044532
Drug: Combined arms
Normalized name: ARM-210
DrugBank: ARM-210 (DB16944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined arms with chemotherapy and/or immunotherapy
Study: 31918243
Drug: Motor-phonetic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motor-phonetic treatment
Study: 31918243
Drug: Combined phonetic-phonological
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined phonetic-phonological treatment
Study: 30477763
Drug: High-dose subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose subcutaneous treprostinil (target dose around 30 ng/kg per min at week 12)
Study: 30477763
Drug: Low-dose subcutaneous
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose subcutaneous treprostinil (target dose around 3 ng/kg per min at week 12)
Study: 30477763
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of high-dose vs low-dose subcutaneous treprostinil
Study: 26919407
Drug: Cavuplasty (creating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cavuplasty (creating a small cavity in the vertebral body prior to cement injection)
Study: 27385833
Drug: Two consecutive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two consecutive real cervical spinal manipulative therapy (SMT) interventions to C5‐C6 segment
Study: 21936966
Drug: Selenomethionine (SeMet)
Normalized name: selenomethionine
DrugBank: Selenomethionine (DB11142)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Selenomethionine (SeMet) supplementation at doses of 0, 50, 100, or 200 μg/d
Study: 17600165
Drug: Cognitive-behavior treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavior treatment (CBT)
Study: 8145914
Drug: 2.0 mg
Normalized name: LORAZEPAM 2.0 mg in 1 mL INTRAVENOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 mg Dihydroergotamine (DHE) nasal spray (0.5 mg per nostril, repeated after 15 minutes)
Study: 3062540
Drug: Ketorolac tromethamine
Normalized name: Ketorolac Tromethamine
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketorolac tromethamine solution 0.5% (1 drop 3 times daily)
Study: 3062540
Drug: Placebo vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo vehicle solution
Study: 3062540
Drug: Ketorolac tromethamine
Normalized name: Ketorolac Tromethamine
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketorolac tromethamine solution 0.5%
Study: 31407622
Drug: Pushen capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pushen capsule
Study: 31407622
Drug: Pushen capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pushen capsule and Ginkgo biloba
Study: 29148175
Drug: Probiotic cocktail
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic cocktail (Lactobacilli, Bifidobacteria, and Streptococcus thermophilus) once daily for 12 weeks
Study: 25846824
Drug: Activities of
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activities of daily living (ADL) score <12 of 15
Study: 21894687
Drug: Eye acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eye acupuncture therapy
Study: 21894687
Drug: Ibuprofen Sustained
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen Sustained Release Capsules, 300 mg orally, 1-2 days before menses or when symptoms appeared, every 12 hours for 3-5 days
Study: 16739330
Drug: High-dose neoadjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose neoadjuvant treatment with cyclophosphamide and epirubicin
Study: 11511713
Drug: Sildenafil citrate
Normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sildenafil citrate (Viagra) 50 mg
Study: 29269513
Drug: BMS‐986120 (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMS‐986120 (60 mg)
Study: 25939641
Drug: Oral sucrose
Normalized name: TootSweet 24% Oral Sucrose Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral sucrose + facilitated tucking
Study: 25939641
Drug: Non-nutritive sucking
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-nutritive sucking + oral sucrose
Study: 25939641
Drug: Non-nutritive sucking
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-nutritive sucking + oral sucrose + facilitated tucking
Study: 19406976
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg phosphorus meal
Study: 19406976
Drug: 1200 mg
Normalized name: aspirin 1200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg phosphorus meal
Study: 11773672
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese medicine (specific intervention not detailed)
Study: 11773672
Drug: Conventional drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional drug development model (implied control)
Study: 12145765
Drug: Fructose (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fructose (75 g)
Study: 28549436
Drug: Cross-linked sodium
Normalized name: riboflavin 5'-phosphate
DrugBank: Flavin mononucleotide (DB03247)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cross-linked sodium hyaluronate (XLHA, single injection)
Study: 28549436
Drug: High molecular
Normalized name: dextran, high molecular weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: High molecular weight sodium hyaluronate (HMWHA, three injections)
Study: 18555517
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of activated autologous T cells
Study: 17031403
Drug: Interleukin-2 (IL-2)
Normalized name: Fusion protein comprised of a circularly-permuted interleukin-2 (IL-2) with the extracellular domain of IL-2 receptor alpha
DrugBank: Human interleukin-2 (DB14865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interleukin-2 (IL-2) group; received four doses of 10 x 10(6) IU m(‐2) twice daily subcutaneously a week before operation followed by a daily maintenance dose of 3 x 10(6) IU m(‐2) subcutaneously until a day before the operation.
Study: 17031403
Drug: Interleukin-2 (IL-2)
Normalized name: Fusion protein comprised of a circularly-permuted interleukin-2 (IL-2) with the extracellular domain of IL-2 receptor alpha
DrugBank: Human interleukin-2 (DB14865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interleukin-2 (IL-2) group; received IL-2 treatment.
Study: 15334869
Drug: Oral glutamine
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral glutamine (10 grams three times a day for 5 days)
Study: 17168431
Drug: Oral glutamine
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral glutamine
Study: 10845968
Drug: Interventions to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interventions to change professional practice in primary care; specific details on dosage and duration not available.
Study: 7710841
Drug: Transfusion treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transfusion treatment
Study: 3236318
Drug: Amiloride 5
Normalized name: amiloride 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiloride 5 mg once daily
Study: 17885562
Drug: Nitrendipine 20
Normalized name: nitrendipine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine 20 mg twice daily
Study: 25526733
Drug: Everolimus (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus (70 mg/wk) with temozolomide and radiotherapy
Study: 17156464
Drug: Acupuncture (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture (up to 10 treatments over 3 months)
Study: 10933361
Drug: Omapatrilat (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omapatrilat (high dose)
Study: 8299252
Drug: Intermittent high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent high-dose pulse cyclophosphamide (Cy) and oral prednisone
Study: 8299252
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral low-dose cyclophosphamide (Cy) and oral prednisone
Study: 8299252
Drug: High-dose co-trimoxazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose co-trimoxazole therapy
Study: 3032814
Drug: Intramuscular iodinated
Normalized name: Iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular iodinated oil given before conception
Study: 3032814
Drug: Intramuscular iodinated
Normalized name: Iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular iodinated oil
Study: 8853757
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg omeprazole daily for 9 days
Study: 8853757
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg omeprazole daily for 9 days
Study: 8853757
Drug: Long-term therapy
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term therapy with omeprazole (mean duration 56 months) in GERD patients
Study: 3883917
Drug: Etretinate (Tigason)
Normalized name: etretinate
DrugBank: Etretinate (DB00926)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Etretinate (Tigason) up to 0.5 mg/kg/day
Study: 30153464
Drug: 13-min daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: 13-min daily guided meditation session for 8 weeks
Study: 30153464
Drug: 13-min daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: 13-min daily podcast listening session (control group) for 8 weeks
Study: 24270743
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of HFABP and troponin
Study: 22095207
Drug: Standard rehabilitation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard rehabilitation plus NMES applied to the quadriceps muscle, initiated 48 hours after surgery, applied twice per day at maximum tolerable intensity for 15 contractions.
Study: 18663117
Drug: Ultrasound (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound (1 MHz, 0.5 W/cm(2)) once daily, six times a week for seven weeks (Groups 1 and 3)
Study: 18663117
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (Groups 1 and 2)
Study: 18663117
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment with ultrasound (Group 3)
Study: 16351668
Drug: EZE/SIMVA 10/20
Approvals — FDA: no, EMA: no, PMDA: no
Description: EZE/SIMVA 10/20 mg/day
Study: 16846545
Drug: ATV 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATV 20 mg/day
Study: 11915724
Drug: Surgery combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery combined with chemo- and/or radiation therapies
Study: 10342337
Drug: Humalog insulin
Normalized name: insulin lispro Cartridge [Humalog]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Humalog insulin
Study: 16321271
Drug: Human soluble
Normalized name: Recombinant human soluble insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human soluble insulin
Study: 25027478
Drug: Cognitive Remediation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Remediation Therapy for 8 weeks followed by Cognitive Behavioral Therapy for 8 weeks
Study: 29738810
Drug: Conventional cigarettes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional cigarettes (CC)
Study: 19317065
Drug: Magnesium group
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium group (MgSO4 30 mg/kg in saline)
Study: 17410461
Drug: Omeprazole 10
Normalized name: omeprazole 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 10 mg once daily (od)
Study: 17410461
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg once daily (od)
Study: 17410461
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg once daily (od)
Study: 17410461
Drug: Omeprazole 10
Normalized name: omeprazole 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 10 mg twice daily (bid)
Study: 27289472
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg twice daily (bid)
Study: 15626258
Drug: Tetracaine/adrenaline solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetracaine/adrenaline solution
Study: 11223706
Drug: CC +
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC + ethinyl estradiol (0.05 mg)
Study: 11223706
Drug: CC +
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC + ethinyl estradiol (0.02 mg)
Study: 2811377
Drug: Vaginal oestriol
Normalized name: estriol Vaginal Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal oestriol (E3) therapy at a dose of 0.5 mg per day
Study: 2811377
Drug: Vaginal oestradiol
Normalized name: estradiol Vaginal Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal oestradiol (E2) therapy at a dose of 0.05 mg per day
Study: 2811377
Drug: Vaginal E3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal E3 therapy
Study: 31438878
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate (MgSO4) infusion for 72 hours
Study: 31438878
Drug: Placebo infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo infusion for 72 hours
Study: 31438878
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate (MgSO4) as second line therapy in observational cohort
Study: 28438473
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus bevacizumab (15 mg/kg every 3 weeks)
Study: 28438473
Drug: Standard chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard chemotherapy (paclitaxel 175 mg/m2 and carboplatin AUC 5)
Study: 19377755
Drug: Cimetidine 35
Normalized name: cimetidine 350 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 35 mg/Kg/day (maximum 1200 mg/day) for three months
Study: 19377755
Drug: Zinc sulphate
Normalized name: Zinc sulphate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc sulphate 10 mg/Kg/day (maximum 600 mg/day) for three months
Study: 17617271
Drug: TMC125 (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMC125 (200 mg) twice daily with darunavir-ritonavir and other antiretrovirals
Study: 11256874
Drug: Conjugated estrogen
Normalized name: Conjugated estrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conjugated estrogen (0.625 mg/d, Premarin) and medroxyprogesterone acetate (5 mg/d, Farlutal)
Study: 11907941
Drug: Continuous progestin
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous progestin regimen in combination with estrogen
Study: 8041979
Drug: Clonidine (0.005
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (0.005 mg/kg/po)
Study: 8041979
Drug: Lorazepam (0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam (0.03 mg/kg/po)
Study: 31758835
Drug: Topical latanoprost
Normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Topical latanoprost gel twice daily for 12 weeks
Study: 19924010
Drug: CHO (6%
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHO (6% carbohydrate supplement)
Study: 19924010
Drug: CHO/PRO L
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHO/PRO L (3% carbohydrate plus 0.75% protein complex)
Study: 19924010
Drug: CHO, CHO/PRO
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHO, CHO/PRO H, CHO/PRO L
Study: 1715450
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of hydrochlorothiazide and triamterene
Study: 1826071
Drug: Diuretics alone
Normalized name: hydralazine hydrochloride / hydrochlorothiazide / reserpine Oral Tablet [Diuretic Ap-Es]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretics alone or diuretics plus methyldopa
Study: 7333741
Drug: Trial A
Normalized name: Trial Antacid
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trial A (3 days L, 3 days H)
Study: 25751329
Drug: Half-dose group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half-dose group (methotrexate 0.15 mg/kg weekly)
Study: 25751329
Drug: 2-weekly group
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-weekly group (methotrexate 0.3 mg/kg every 2 weeks)
Study: 24176390
Drug: Inhaled aztreonam
Normalized name: aztreonam Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled aztreonam (AZLI)
Study: 22902212
Drug: Bevacizumab (intraocular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (intraocular injections every 6 weeks for 12 months)
Study: 22902212
Drug: Sham injections
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham injections (first 6 months), then Bevacizumab (intraocular injections every 6 weeks for 6 months)
Study: 17882731
Drug: Mebeverine hydrochloride
Normalized name: Mebeverine hydrochloride
DrugBank: Mebeverine (DB12554)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mebeverine hydrochloride film-forming gel
Study: 15333608
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of physical exercise and high altitude (Protocol III)
Study: 9475762
Drug: Finasteride (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finasteride (5 mg daily for four years)
Study: 8553300
Drug: Twice daily
Normalized name: CAPSULE, TWICE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily inhaled budesonide (400 micrograms morning and bedtime)
Study: 8553300
Drug: Once daily
Normalized name: GEL, ONCE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily inhaled budesonide (800 micrograms at bedtime)
Study: 436626
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg digoxin by mouth
Study: 436626
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg beta-acetyldigoxin by mouth
Study: 436626
Drug: Orally administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally administered digoxin
Study: 436626
Drug: Orally administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally administered beta-acetyldigoxin
Study: 436626
Drug: Intravenously administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenously administered digoxin
Study: 29976285
Drug: Rivaroxaban 2.5
Normalized name: rivaroxaban 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 2.5 mg orally twice per day